Genentech funds cancer inhibitor development by Inotek

Published: 25-Jul-2006

Biotechnology company Genentech and privately-owned drug developer Inotek Pharmaceuticals have formed a global collaboration to develop and commercialise inhibitors of poly (ADP-ribose) polymerase (PARP) for the treatment of cancer.


Biotechnology company Genentech and privately-owned drug developer Inotek Pharmaceuticals have formed a global collaboration to develop and commercialise inhibitors of poly (ADP-ribose) polymerase (PARP) for the treatment of cancer.

PARP is a nuclear enzyme within cells that directs the repair of damaged DNA and it has applications in the treatment of oncology and cardiovascular conditions.

Genentech will pay upfront US$20m to Inotek, with the potential for up to $405m in additional milestone payments. It will also pay royalties based on the net amount of any sales of Inotek's lead PARP Inhibitor, INO-1001, or other next-generation PARP inhibitors in the field of cancer. In addition, it will also provide funding to utilise Inotek's small molecule chemistry expertise as part of a multi-year collaborative research programme and will pay for all future clinical development costs of INO-1001 and subsequent PARP inhibitors in cancer.

Genentech has retained an option to develop and commercialise Inotek's PARP inhibitors to prevent cell death and complications associated with various acute cardiovascular conditions and procedures. This option, if exercised, could be worth as much as $200 million in additional payments to Inotek.

Inotek has retained an option to co-promote PARP inhibitors in the acute cardiovascular field in the US with Genentech and has retained all rights to develop and commercialise PARP inhibitors outside of cancer and the specific acute cardiovascular diseases included in Genentech's option.

INO-1001 represents Inotek's lead compound in a series of novel PARP inhibitors discovered by Inotek. INO-1001 is currently in Phase Ib testing for malignant melanoma in combination with temozolomide.

See more

You may also like

Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

Read more
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Subscribe now